SHANGHAI, May 20, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the supplemental application for MAIWEIJIAN (Denosumab Injection, R&D code: 9MW0321), which was independently...
Hence then, the article about mabwell announces nmpa approval of supplemental application for additional indications of maiweijian denosumab injection was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Mabwell Announces NMPA Approval of Supplemental Application for Additional Indications of MAIWEIJIAN (Denosumab Injection) )
Also on site :
- Inter Miami vs Atlanta United: When and Where to Watch the MLS Match
- Mandy Moore on Hilary Duff’s Musical Comeback and Playing an ‘Absolute Bitch’ in Dan Fogelman’s NFL Family Drama ‘The Land’: It’s ‘”Friday Night Lights” and “Succession” All Rolled Into One’
- ‘The Liberation’ Review: Carrie Coon Is Breathtaking as a Woman Lured by a Cult in Guy Nattiv’s Deeply Personal Film